References:
1. Magne J, Pibarot P, Sengupta PP, Donal E, Rosenhek R, Lancellotti
P. Pulmonary hypertension in valvular disease: a comprehensive review on
pathophysiology to therapy from the HAVEC Group. JACC Cardiovasc
Imaging (2015) 8(1):83–99. 10.1016/j.jcmg.2014.12.003
[PubMed]
[CrossRef] [Google
Scholar
2 .Rich S, Rubin LJ, Abenhail L, et al. Executive Summary From the World
Symposium on Primary Pulmonary Hypertension (Evian, France; September
6–10, 1998). Geneva, Switzerland: World Health
Organization; 1998:1–27.Google Scholar
3. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular
disease; a description of six grades of structural changes in the
pulmonary arteries with special reference to congenital cardiac septal
defect. Circulation . 1958;18(4, pt 1):533–547
4. Weitsman T, Weisz G, Farkash R, Klutstein M, Butnaru A, Rosenmann D,
et al. Pulmonary hypertension with left heart disease: prevalence,
temporal shifts in etiologies and outcome. Am J
Med (2017) 130(11):1272–9. 10.1016/j.amjmed.2017.05.003
[PubMed]
[CrossRef] [Google
Scholar]
5. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical
classification of pulmonary hypertension published correction appears inJ Am Coll Cardiol . 2014; 63(7):746]. J Am Coll Cardiol.
2013;62(25)(suppl):D34–D41.
6. N. Galie, M. Humbert, J.L. Vachiery, et
al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of
pulmonary hypertension: The Joint Task Force for the Diagnosis and
Treatment of Pulmonary Hypertension of the European Society of
Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed
by: Association for European Paediatric and Congenital Cardiology
(AEPC). International Society for Heart and Lung Transplantation (ISHLT)
Eur Heart J, 37 (2016), pp. 67-119